PRC
TGTX icon

Pearl River Capital’s TG Therapeutics TGTX Stock Holding History

Pearl River Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-54,857
Closed -$976K – 338
2024
Q2 		$976K Buy
+54,857
New +$875K 0.16% 188
2020
Q4 		– Sell
-12,631
Closed -$338K – 501
2020
Q3 		$338K Sell
12,631
-7,459
-37% -$172K 0.14% 227
2020
Q2 		$391K Buy
+20,090
New +$324K 0.19% 171

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pearl River Capital's TGTX Position: Q3 2024 in Review

Pearl River Capital sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 54,857 shares — an estimated $976K sold.

Pearl River Capital first reported a position in TGTX in Q2 2020 and held it in 3 quarters. The position peaked at $976K in Q2 2024. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • Pearl River Capital reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pearl River Capital sold 54,857 TG Therapeutics shares in Q3 2024, an estimated $976K.
  • Pearl River Capital first reported a position in TG Therapeutics in Q2 2020 and held it in 3 quarters.
  • Pearl River Capital's TG Therapeutics position peaked at $976K in Q2 2024.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Pearl River Capital's 13F filing for Q3 2024.